

Maelor Laboratories Limited
Financial Statements
For the year ended 31 December 2022



Company number 03357249

Maelor Laboratories Limited
Financial statements for the year ended 31 December 2022

1

Company Information

Registered office	Avonbridge House Bath Road Chippenham Wiltshire SN15 2BB
Director	P J Butterfield A T Franklin A J H Duggan S M Kidner (resigned 27 September 2022)
Secretary	C T Chrysanthou
Company number	03357249

Directors' Report

The directors present their directors' report together with the unaudited financial statements of the company for the year ended 31 December 2022. The company is dormant and has not traded during the year.

Directors

The directors who served the company during the year were:

P J Butterfield

A T Franklin

A J H Duggan

S M Kidner (resigned 27 September 2022)

The company is a wholly owned subsidiary and the interests of the group directors are disclosed in the financial statements of the parent company.

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read 'A T Franklin', with a stylized flourish at the end.

Andrew Franklin

Director

29 August 2023

Financial statements for the year ended 31 December 2022


Balance sheet

		31 December 2022	31 December 2021
	Note	£000	£000
Current assets			
Debtors	3	25	25
Total assets		<u>25</u>	<u>25</u>
Capital and reserves			
Called-up equity share capital	5	-	-
Profit and loss account		25	25
Shareholders' funds		<u>25</u>	<u>25</u>

Statements:

- (a) For the year ended 31 December 2022 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
- (b) The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
- (c) The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

These financial statements were approved by the directors and authorised for issue on 29 August 2023, and are signed on their behalf by:



Andrew Franklin

Director

Company number 03357249

The accompanying accounting policies and notes form part of these financial statements.

Maelor Laboratories Limited
Notes to the Financial statements
for the year ended 31 December 2022

4

1 Dormant status

The company was dormant (within the meaning of Section 480 of the Companies Act 2006) throughout the year ended 31 December 2022. The company has not traded during the year or during the preceding financial year. During these periods, the company received no income and incurred no expenditure and therefore made neither profit nor loss.

2 Profit and loss account

The company did not trade during the year and has made neither a profit nor a loss. No Statement of Profit and Loss Account has been prepared.

3 Debtors

	2022 £000	2021 £000
Amounts owed by group undertakings	25	25

4 Related party transactions

The company is a wholly owned subsidiary and the accounts of the parent company are available. Therefore, the company is exempt from disclosing related party transactions.

5 Share capital

Authorised share capital:

	2022 £	2021 £
2 Ordinary shares of £1 each	2	2

Allotted, called up and fully paid:

	2022		2021	
	No	£	No	£
Ordinary shares of £1 each	2	2	2	2

6 Ultimate parent company

The company is a 100% owned subsidiary of Alliance Pharmaceuticals Limited, a company registered in England and Wales. The directors consider that the ultimate parent undertaking and controlling related party of the company is Alliance Pharma plc by virtue of its 100% shareholding in Alliance Pharmaceuticals Limited. The largest and smallest group undertaking for which group accounts have been prepared is that prepared by Alliance Pharma plc. These accounts are available from the registered office of that company.